ENB-003 is under clinical development by ENB Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect ENB-003’s likelihood of approval (LoA) and phase transition for Pancreatic Cancer took place on 22 Apr 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ENB-003 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
ENB-003 is under development for the treatment of glioblastoma multiforme, platinum-resistant ovarian, pancreatic cancer, head and neck cancer squamous cell carcinoma, stage IIB to IV malignant melanoma, high-grade endometroid cancer, fallopian tube, primary peritoneal carcinoma, leiomyosarcoma, poorly differentiated or dedifferentiated liposarcoma, undifferentiated pleomorphic sarcoma, malignant fibers histiocytoma, synovial sarcoma, Ewings sarcoma, osteosarcoma and dedifferentiated or mesenchymal chondrosarcoma. The drug candidate is deuterium exchanged NCE derivative of BQ788 and second generation new chemical entity that act by targeting endothelin B receptor (ETBR). They are delivered using nanotechnology delivery systems.
ENB Therapeutics overview
ENB Therapeutics is a biopharmaceutical company. The company is developing therapies to break drug resistance that occurs in over cancer patients and the tumor microenvironment to hide cancer cells from immune system attack. It is headquartered in New York, United States.
Quick View ENB-003 LOA Data
|Highest Development Stage|